Authors
Latest:
Dr. Grady on Gene Profiling of CTCs in Pancreatic CancerWilliam M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from an ongoing prospective study looking at gene expression profiling of circulating tumor cells in patients with unresectable pancreatic cancer.
Latest:
Dr. Oh on the Management of Hormone-Sensitive Prostate CancerWilliam Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the management of patients with hormone-sensitive prostate cancer.
Latest:
Dr. Tew Evaluates Avastin Treatment in Ovarian CancerWilliam P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer
Latest:
Direct Targeting of RET Aberrations Moves Closer to the ClinicOver the past 30 years, from the discovery of a fusion rearrangement to the recent promise of LOXO-292, RET targeting has gone from distant concept toward clinical reality.
Latest:
Dr. Berry on Novel Imaging Techniques for Prostate CancerWilliam R. Berry, MD, medical oncologist, Duke University, discusses novel imaging techniques for patients with prostate cancer.
Latest:
Dr. Gwin on Potential Areas of Investigation With Alpha-TEA/Trastuzumab in Breast CancerWilliam R. Gwin III, MD, discusses potential areas of investigation with the combination of alpha-tocopheryloxyacetic acid (alpha-TEA) and trastuzumab (Herceptin) in breast cancer.
Latest:
Dr. Jarnagin on Surgical Protocols for CRC That Have Spread Beyond the LiverWilliam R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.
Latest:
Dr. Jarnagin on the Improvements in Surgery for Patients With mCRCWilliam R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.
Latest:
Palliative Care Issues in Gynecologic CancerPalliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.
Latest:
Dr. DeRosa Discusses Nab-Paclitacel in Lung CancerWilliam T. DeRosa, DO, from Carol G. Simon Cancer Center at Morristown Memorial Hospital, discusses subset analyses from the phase III CA031 trial that examined nab-paclitaxel in non-small cell lung cancer.
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment RecommendationsResearchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Latest:
Individualized Approach to Treatment for the Elderly Ovarian Cancer PatientStuart Lichtman, MD, and William Tew, MD, from Memorial Sloan-Kettering Cancer Center, discuss personalizing treatment for elderly patients with ovarian cancer.
Latest:
Smartphones Moving to the Front Line of Mobile Technology for PhysiciansTraditionally, physicians have relied on textbooks, conferences, and, more recently, the Internet to keep abreast of the latest clinical data and support clinical decision-making
Latest:
CLL: Final ThoughtsAn expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Latest:
Novel Proteasome Inhibitors for Multiple MyelomaMultiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.
Latest:
Dr. Gerritsen on a Study of Alisertib in Neuroendocrine Prostate CancerWinald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the activity of alisertib monotherapy in patients with neuroendocrine prostate cancer.
Latest:
Dr. Tan on Imaging Modalities in Prostate CancerWinston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses imaging modalities in prostate cancer.
Latest:
Dr. Wojciech Jurczak on MOR208 in Non-Hodgkin's LymphomaWojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
Latest:
Dr. Fendler on Impact of 68Ga-PSMA-11 PET on Prostate Cancer ManagementWolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.
Latest:
Dr. Hiddemann on Updated Results of Immunochemotherapy Study in Follicular LymphomaWolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.
Latest:
Dr. Janni on the Influence of Biosimilars in OncologyWolfgang Janni, MD, PhD, professor and chair of the Department of Obstetrics and Gynecology at the University of Ulm, Germany, discusses the influence of biosimilars in oncology.
Latest:
Dr. Bosch Discusses the Importance of the HPV VaccineXavier Bosch, MD, MPH, Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia–Catalan Institute of Oncology, discusses the importance of the HPV vaccine in the prevention of cervical cancer.
Latest:
Dr. Wei on Immune-Related Adverse Events in GU CancersXiao X. Wei, MD, MAS, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immune-related adverse events (irAE) in genitourinary (GU) cancers.
